The study revealed that the intestinal bacteri group affects the efficacy of acapolyptic sugar-lowering drugs

Reporters from Shanghai Jiaoda University School of Medicine affiliated Ruijin Hospital was informed that the hospital Ningguang academician team and the University of China Institute of Life Sciences jointly completed a study results show that the same use of akabo sugar to treat diabetes, B enteric intestinal bacteriospoon population significantly better results, weight loss, fat reduction and improve insulin resistance is more obvious, and revealed the reasons. Happily, the proportion of people Chinese B enteric intestinal bacteria is higher among these groups.
has long been widely used in the treatment α diabetic patients with acapolypse (small intestine α glucosidease inhibitors. Doctors have found in the clinic that compared to traditional sulfonylurea drugs, acapolypse can be used in some diabetic patients to control blood sugar other than the effect, including weight loss, blood lipid loss and so on.
team first conducted a controlled study of 106 patients with type 2 diabetes who had not yet received medication, and randomly assigned patients to take the acabo sugar group and gretazine group. After three months of treatment, the researchers found that acapolypse was indeed more effective at improving a patient's weight, insulin resistance, and blood lipids than greasing. On this basis, the researchers classified the intestinal symblotic bacteri groups of these patients with type 2 diabetes before taking the drug, and obtained two different types: E. coli-rich, or B-type, rich in Platts enterobacteria, or P-type. They found that people with bowel type B showed more metabolic benefits after receiving acapolypse treatment, such as weight loss, fat loss, and improved insulin resistance.
the researchers further used high-volume sequencing combined with bio-informational analysis in the hope of revealing an intrinsic link between the intestinal bacteria's involvement in the drug's effectiveness. The study found that there are more probiotics such as Bifidobacteria and lactic acid bacteria in the body of type B bacterium, which helps digestion, while the body of type B bacteria lacks such bacteria that help digestion. The researchers believe this may be one of the reasons why acapolypse has benefited so much in this group.
first time that we have looked at the drug response to diabetes treatment and found differences in the therapeutic effects of different bowel types on acapolypse, " he said. Ning Guang, a member of the Chinese Academy of Engineering, said similar group classifications had been found in previous studies of the genomes of normal people abroad, but no link had been found between such groups and human diseases or metabolic abnormalities. Professor Wang Weiqing, of the endocrinology department at Ruijin Hospital, explains that Acapo sugar is likely to benefit from various metabolic improvements other than sugar reduction by altering the bile acid metabolism of gut microorganisms.
This is the first international study to establish the relationship between the efficacy of sugar-lowering drugs and the characteristics of intestinal symbica, which not only solves the mystery of the mechanism by which a common sugar-lowering drug brings benefits to sugar-lowering metabolism, but also provides new ideas for the future design of new diabetes drugs targeting the metabolism of bile acid in intestinal symbica bacteria. The results of the research have
published in The Times. (Source: Xinhua News Agency, Qiu Yi